Moleculin Biotech
MBRX
28 hedge funds and large institutions have $10.9M invested in Moleculin Biotech in 2021 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 6 closing their positions.
500% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 1
23% more capital invested
Capital invested by funds: $8.88M → $10.9M (+$2.05M)
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
4% more funds holding
Funds holding: 27 → 28 (+1)
0.01% more ownership
Funds ownership: 0.02% → 0.03% (+0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.11M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$229K |
| 3 |
State Street
Boston,
Massachusetts
|
+$218K |
| 4 |
SCM
Sio Capital Management
New York
|
+$153K |
| 5 |
BlackRock
New York
|
+$138K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
-$136K |
| 2 |
Squarepoint
New York
|
-$118K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$111K |
| 4 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$109K |
| 5 |
Charles Schwab
San Francisco,
California
|
-$50K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| $1K | – | – | – |
|
|
GRP
27
Global Retirement Partners
San Rafael,
California
| $1K | – | – | – |
|
|
NSIM
28
North Star Investment Management
Chicago,
Illinois
| $1K | – | – | – |
|
|
PWMG
29
Prestige Wealth Management Group
Flemington,
New Jersey
| $1K | – | – | – |
|
30
Wells Fargo
San Francisco,
California
| $1K | – | – | – |
|
|
31
Squarepoint
New York
| – | -$118K | -77 | Closed |
|
|
TSS
32
Two Sigma Securities
New York
| – | -$111K | -73 | Closed |
|
|
CSS
33
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$109K | -71 | Closed |
|
|
34
Charles Schwab
San Francisco,
California
| – | -$50K | -32 | Closed |
|
|
HIIFS
35
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
| – | -$136K | -27 | Closed |
|
|
SPIA
36
Steward Partners Investment Advisory
New York
| – | -$4.08K | -3 | Closed |
|
MBRX Hedge Fund Activity: Q2 2021 in Review
28 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q2 2021, worth a combined $10.9M — up 23% from $8.88M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new MBRX positions and 6 closed out — a net gain of 1 holder — while 6 added to existing stakes and 1 trimmed.
The largest buyer was Vanguard Group, adding an estimated $2.11M. The largest seller was Harel Insurance Investments & Financial Services, exiting entirely with an estimated $136K sold.
- 28 institutional investors held Moleculin Biotech (MBRX) as of Q2 2021, up from 27 in Q1 2021.
- Funds reported $10.9M of Moleculin Biotech stock for Q2 2021, up 23% quarter-over-quarter.
- 7 funds opened new Moleculin Biotech positions in Q2 2021 and 6 closed out, a net change of +1 holder.
- The largest Moleculin Biotech buyer in Q2 2021 was Vanguard Group, an estimated $2.11M added.
- The largest Moleculin Biotech seller in Q2 2021 was Harel Insurance Investments & Financial Services, an estimated $136K sold.
Based on aggregated 13F filings for Q2 2021.